NASDAQ:SANA

Sana Biotechnology Stock Forecast, Price & News

$25.51

+1.31 (+5.41 %)

(As of 04/14/2021 12:54 PM ET)

Add

Compare

Today's Range

$24.33

Now: $25.51▼

$26.43

50-Day Range

$23.04

MA: $30.42▼

$37.85

52-Week Range

$21.21

Now: $25.51▼

$44.60

Volume9,919 shs

Average Volume666,329 shs

Market Capitalization$4.78 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops in vivo and ex vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:SANA

Previous Symbol

CUSIPN/A

CIKN/A

Websana.com

Phone206 701 7914

EmployeesN/A

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current RatioN/A

Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book ValueN/A

Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares187,506,000

Market Cap$4.78 billion

Next Earnings Date6/23/2021 (Estimated)

OptionableNot Optionable

Headlines

Sana Biotechnology (NASDAQ:SANA) Trading 8.2% Higher
April 14, 2021 | americanbankingnews.com

Biotech R&D Startup Benchling Hits $4 Billion Valuation As The Company Starts Laying Groundwork For An IPO
April 14, 2021 | forbes.com

Sana Biotechnology (NASDAQ:SANA) Shares Down 10.7%
April 12, 2021 | americanbankingnews.com

Sana Biotechnology Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2021
April 9, 2021 | finance.yahoo.com

Sana Biotechnology (NASDAQ:SANA) Sees Large Volume Increase
April 6, 2021 | americanbankingnews.com

Real Estate Deals: Ventas makes a billion-dollar bet in biotech's epicenter
April 2, 2021 | bizjournals.com

Sana Biotechnology (NASDAQ:SANA) Trading Down 4.2%
April 1, 2021 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Sees Strong Trading Volume
March 31, 2021 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Shares Gap Down After Earnings Miss
March 26, 2021 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Stock Price Down 5.8% on Disappointing Earnings
March 25, 2021 | americanbankingnews.com

Sana Biotechnology (NASDAQ:SANA) Posts Quarterly Earnings Results, Misses Estimates By $2.57 EPS
March 25, 2021 | americanbankingnews.com

Sana Biotechnology Reports Fourth Quarter and 2020 Financial Results and Business Updates
March 24, 2021 | finance.yahoo.com

FUJIFILM Cellular Dynamics and Sana Biotechnology Announce License Agreement for the Development of iPSC-Derived Cell Therapies
March 17, 2021 | finance.yahoo.com

Sana Biotechnology Inc Registered Shs Overweight
March 3, 2021 | markets.businessinsider.com

Sana Biotechnology Inc Registered Shs Neutral
March 3, 2021 | markets.businessinsider.com

Sana Biotechnology Inc
February 20, 2021 | reuters.com

Sana Biotechnology: An Ultra-Risky Bet
February 10, 2021 | seekingalpha.com

Sana Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 8, 2021 | finance.yahoo.com

Sana Biotech valued at over $6 billion in market debut
February 6, 2021 | reuters.com

US IPO Weekly Recap: Biotechs flood the IPO market in a 14 IPO week
February 6, 2021 | nasdaq.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.15 out of 5 stars

Medical Sector

957th out of 2,019 stocks

Biotechnology Industry

37th out of 145 stocks

3.3 Analyst's Opinion

Consensus Rating
Sana Biotechnology has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $40.00, Sana Biotechnology has a forecasted upside of 55.6% from its current price of $25.71.
Amount of Analyst Coverage
Sana Biotechnology has only been the subject of 4 research reports in the past 90 days.

2.5 Community Rank

Outperform Votes
Sana Biotechnology has received 4 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Sana Biotechnology has received 4 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Sana Biotechnology has received 50.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Sana Biotechnology and other stocks. Vote “Outperform” if you believe SANA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SANA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Sana Biotechnology does not currently pay a dividend.
Dividend Growth
Sana Biotechnology does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sana Biotechnology insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

$25.51

+1.31 (+5.41 %)

(As of 04/14/2021 12:54 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive SANA News and Ratings via Email

Sign-up to receive the latest news and ratings for SANA and its competitors with MarketBeat's FREE daily newsletter.

Sana Biotechnology (NASDAQ:SANA) Frequently Asked Questions

Is Sana Biotechnology a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sana Biotechnology in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Sana Biotechnology stock.
View analyst ratings for Sana Biotechnology or view top-rated stocks.

What stocks does MarketBeat like better than Sana Biotechnology?

Wall Street analysts have given Sana Biotechnology a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sana Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sana Biotechnology's next earnings date?

Sana Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, June 23rd 2021.
View our earnings forecast for Sana Biotechnology.

How were Sana Biotechnology's earnings last quarter?

Sana Biotechnology, Inc. (NASDAQ:SANA) issued its quarterly earnings data on Tuesday, March, 23rd. The company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of ($0.41) by $2.57.
View Sana Biotechnology's earnings history.

What price target have analysts set for SANA?

4 analysts have issued 1-year target prices for Sana Biotechnology's shares. Their forecasts range from $35.00 to $45.00. On average, they expect Sana Biotechnology's share price to reach $40.00 in the next twelve months. This suggests a possible upside of 57.7% from the stock's current price.
View analysts' price targets for Sana Biotechnology or view top-rated stocks among Wall Street analysts.

Who are Sana Biotechnology's key executives?

Sana Biotechnology's management team includes the following people:

Dr. Steven D. Harr, Pres, CEO & Director (Age 51, Pay $535k)
Dr. Richard C. Mulligan, Exec. Vice Chairman & Head of SanaX (Age 66, Pay $756.45k)
Mr. Christian Hordo M.B.A., Sr. VP & Chief Bus. Officer (Age 38, Pay $350.2k)
Mr. Nathan Hardy M.B.A., Sr. VP & CFO (Age 45)
Ms. Shanna Clouse Peek, Sr. VP & Head of Corp. Operations
Brittany Mccleery, Accounting Mang.
Dr. Edward Rebar Ph.D., Sr. VP & CTO (Age 53)
Mr. James J. MacDonald J.D., Exec. VP, Gen. Counsel & Sec. (Age 46)
Ms. Robin Andrulevich, Exec. VP & Chief People Officer (Age 55)
Dr. Sunil Agarwal, Exec. VP, Head of Devel. & Chief Medical Officer (Age 51)

Who are some of Sana Biotechnology's key competitors?

Some companies that are related to Sana Biotechnology include AbCellera Biologics (ABCL), Abcam (ABCM), Cronos Group (CRON), Seer (SEER), Genus (GNS), BTG (BTG), Abcam (ABC), MorphoSys (MOR), Nuvation Bio (NUVB), ImmunityBio (IBRX), BioAtla (BCAB), Immunocore (IMCR), Cullinan Oncology (CGEM), Cricut (EWTX) and Trillium Therapeutics (TRIL).
View all of SANA's competitors.

When did Sana Biotechnology IPO?

(SANA) raised $322 million in an initial public offering (IPO) on Thursday, February 4th 2021. The company issued 15,000,000 shares at a price of $20.00-$23.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and BofA Securities acted as the underwriters for the IPO.

What is Sana Biotechnology's stock symbol?

Sana Biotechnology trades on the NASDAQ under the ticker symbol "SANA."

When does the company's lock-up period expire?

Sana Biotechnology's lock-up period expires on Tuesday, August 3rd. Sana Biotechnology had issued 23,500,000 shares in its initial public offering on February 4th. The total size of the offering was $587,500,000 based on an initial share price of $25.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted.

How do I buy shares of Sana Biotechnology?

Shares of SANA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sana Biotechnology's stock price today?

One share of SANA stock can currently be purchased for approximately $25.37.

How much money does Sana Biotechnology make?

Sana Biotechnology has a market capitalization of $4.76 billion.

What is Sana Biotechnology's official website?

The official website for Sana Biotechnology is sana.com.

How can I contact Sana Biotechnology?

The company can be reached via phone at 206 701 7914.

This page was last updated on 4/14/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Sana Biotechnology Stock Forecast, Price & News

Adding

Adding

Adding Sana Biotechnology, Inc.

Industry, Sector and Symbol

Debt

Price-To-Earnings

Sales & Book Value

Profitability

Miscellaneous

Headlines

MarketRank™

Overall MarketRank™

3.3 Analyst's Opinion

Consensus Rating

Price Target Upside/Downside

Amount of Analyst Coverage